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Abstract: The Quality of Life after Traumatic Brain Injury (QOLIBRI) instrument is an internationally
validated patient-reported outcome measure for assessing disease-specific health-related quality of life
(HRQoL) in individuals after traumatic brain injury (TBI). However, no reference values for general
populations are available yet for use in clinical practice and research in the field of TBI. The aim of the
present study was, therefore, to establish these reference values for the United Kingdom (UK) and
the Netherlands (NL). For this purpose, an online survey with a reworded version of the QOLIBRI
for general populations was used to collect data on 4403 individuals in the UK and 3399 in the
NL. This QOLIBRI version was validated by inspecting descriptive statistics, psychometric criteria,
and comparability of the translations to the original version. In particular, measurement invariance
(MI) was tested to examine whether the items of the instrument were understood in the same way
by different individuals in the general population samples and in the TBI sample across the two
countries, which is necessary in order to establish reference values. In the general population samples,
the reworded QOLIBRI displayed good psychometric properties, including MI across countries and
in the non-TBI and TBI samples. Therefore, differences in the QOLIBRI scores can be attributed to real
differences in HRQoL. Individuals with and without a chronic health condition did differ significantly,
with the latter reporting lower HRQoL. In conclusion, we provided reference values for healthy
individuals and individuals with at least one chronic condition from general population samples in
the UK and the NL. These can be used in the interpretation of disease-specific HRQoL assessments
after TBI applying the QOLIBRI on the individual level in clinical as well as research contexts.
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1. Introduction
Traumatic brain injury (TBI) is often a source of long-lasting impairments and functional
limitations [1]. It can affect participation in daily activities [2] and may lead to a stagnation in
working life for several years [3] or permanently prevent a return to work [4]. TBI can have
dramatic consequences for cognitive, behavioral, and emotional life domains, and increases the risk of
experiencing other health-related problems such as increased alcohol consumption and depression [5].
However, a person’s perception of TBI sequelae, compared to an objectively assessed functional state,
is a subjective dimension, and the relationship between these two types of measurement is not always
straightforward [6]. Subjective assessments of health deficits and self-rated health-related quality of
life (HRQoL) provide valuable additional information to clinical health examinations and ratings.
Thus, patient-reported outcomes (PROs) have now become widely used in assessing HRQoL in the
field of TBI. HRQoL measures provide aggregated information on diverse health components, such as
physical, psychological (mental and emotional), social and daily life aspects, and are, therefore, able to
capture the multidimensionality of individually experienced consequences of TBI [7].
A systematic review of assessments of HRQoL after TBI, covering the period from 1991 to
2013, found that the most frequently used instruments were the generic Short Form (36) Health
Survey (SF-36) [8] and the TBI-specific Quality of Life after Traumatic Brain Injury (QOLIBRI) [1].
Both instruments display satisfactory to very good psychometric properties in TBI populations, with the
QOLIBRI having higher discriminative powers when separate domains of the QOLIBRI and SF-36 are
compared [7,9].
To gain a more in-depth understanding of TBI-specific consequences, one may apply a TBI-specific
HRQoL instrument. However, from the perspective of rehabilitation after TBI, applying generic
instruments may offer an advantage due to the availability of population-based reference values.
Bearing in mind the unspecific nature of some post-TBI symptoms, such as headaches and nausea [10],
a comparison with general population samples is essential in order to evaluate the rehabilitation
progress. Additionally, population-based reference values play a key role in differentiating between
individuals after TBI with and without impaired HRQoL.
In previous research, the QOLIBRI was developed and validated exclusively in samples of
individuals after TBI to establish its sensitivity for the TBI condition [11]. In the interest of enhancing
the interpretability of its scores in clinical practice and research after TBI, we collected QOLIBRI scores
from general population samples in the UK and the NL to provide respective reference values.
Thus, the aims of the present study are:
• To ensure the comparability of QOLIBRI translations between general and TBI samples by
determining the measurement invariance (MI) in general population samples (healthy individuals
and individuals with a chronic health condition) and TBI samples from the UK and the NL.
• To provide reference values for healthy individuals and individuals with at least one chronic
health condition from the UK and the NL.
Only when MI has been verified, reference values will be provided for healthy individuals
(and individuals with a chronic health condition) from Dutch and UK general population samples.
Separate reference values will be given for the presence and absence of chronic health conditions, age,
sex, and level of education.
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2. Methods
2.1. Study Design
The present study is a web-based, self-reported, cross-sectional study based on quota sampling
of general population samples from the UK and the NL (see below). Additional data of patients
after TBI, needed for the MI analyses, were retrieved from the multicenter, prospective, longitudinal,
observational Collaborative European Neuro Trauma Effectiveness Research in Traumatic Brain Injury
(CENTER-TBI) study [12]. These data were collected at three months post-TBI.
2.2. Setting
2.2.1. General Population Samples
Data Collection
The general population sample data were collected through a web-based survey. Respondents were
recruited by a market research agency (https://www.dynata.com/), which distributed the questionnaires
and collected the data. The samples were based on existing large internet panels designed to be
representative for individuals from the general population from the UK and the NL with regard to age,
sex, and education. Data collection was carried out between 29 June and 31 July 2017.
The recruitment integrated several sources, e.g., proprietary loyalty partnerships (members of
loyalty programs across travel, entertainment, retail, and other sectors), open recruitment to traditional
online panels (e.g., via online banners, online all panels, cable TV advertising, mailings, social media
influencers, and other methods), and integrated partnerships with online communities, publishers,
and social networks. A broad variety of sources was chosen to reach participants from different social
milieus to thereby increase the representativity of the sample.
To avoid a self-selection bias, no specific project details were included in the invitation: participants
were invited to “take a survey”. Details were disclosed later, after the system had selected the individuals
for participation according to the given selection criteria. After completing the survey, participants
received an incentive in the form of cash, points, prizes, or sweepstakes from the market research
company. Respondents, who were identified by the agency as “speeders” (e.g., who took the survey
in less than five minutes), were deleted. The electronic data capture system did not allow missing
answers, thus respondents had to answer every question. The recruitment process continued until the
required quotas were reached.
Informed Consent
Informed consent for the present survey was obtained by the agency from all those agreeing
to complete the online survey. The process is described in the privacy agreement available at https:
//www.dynata.com/privacy-policy/. Participants were informed on the welcome page of the survey
that its aim was a better understanding of the consequences of TBI on patients’ lives, that it would take
approximately 20 min to complete, and that all responses were confidential and anonymous. Data were
anonymized and each participant was assigned a number in the order of questionnaire completion.
Sample Composition
From a total of 11,759 survey participants, 4646 individuals from the UK and 3564 from the NL
were included for further analyses. Recruitment was carried out until the required quotas for age,
gender, and education had been achieved, which ensured that samples were as comparable as possible
to the general populations of the two countries. Nonresponse rates were below 20% (UK: 14.4%,
NL: 19.5%). A more detailed analysis of these individuals was not possible due to the recruitment
system used.
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Prior to the analyses, responses to QOLIBRI items were examined for obvious contradictory
response patterns in both general population samples, for example, the choice of the response option
“not at all” for all items, meaning that responders were not at all satisfied and at the same time
not at all bothered. This indicated that the person had chosen only left-hand side response options,
ignoring the item polarity. Due to contradictory response patterns, the data of 243 individuals from
the UK and of 165 individuals from the NL general population samples were excluded from further
analyses. The individuals included and excluded were compared using chi-square (χ2-) tests with Yates
correction for nominal variables and independent t-test for continuous variables. In both countries,
excluded individuals were predominantly male and younger compared with the total sample (M = 35,
SD = 12) and had a middle level of education. In the end, 7802 individuals from the general population
(UK: 4403; NL: 3399) were included in the final analyses (see Figure 1).
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2.2.2. TBI sample
Data Collection
Individuals after TBI were investigated in the (CENTER-TBI) study [13]. They were recruited
between 9 December 2014 and 17 December 2017. The inclusion criteria were a clinical diagnosis of TBI,
presentation to hospital within 24 h after the injury, a clinical indication for a computed tomography
(CT) scan, and provision of informed consent adhering to local and national requirements. Data were
collected applying an electronic case report form (e-CRF, QuesGen Systems Incorporated, Burlingame,
CA, USA) either during the hospital visit, in a face-to-face visit, a telephone interview, or by mail
combined with a telephone interview. The data were exported from the CENTER-TBI database,
Neurobot version 2.0, on 8 November 2018. Further study details can be found elsewhere [12].
Inform d Consent
Informed consent was obtained according to local and national requirements for all patients
recruited in the Core Dataset of CENTER-TBI and documented in the e-CRF [13].
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Sample Composition
Out of the total of 4509 CENTER-TBI core study participants, 554 individuals after TBI from the UK
and 936 from the NL participated in the assessments at three months post-TBI and were included in the
present study. When there were less than 30% of missing answers per QOLIBRI subscale, scores were
calculated by using the prorating method [14]. Of the 1490, 830 individuals did not complete the
QOLIBRI at three months.
Chi-square tests with Yates correction for nominal variables and independent t-test for continuous
variables showed that participants from the NL had a higher level of education, were mostly female,
working or studying, and had predominantly sustained a mild TBI (84% in the NL and 72% in the
UK) with a good recovery rated by the Glasgow Coma Scale Extended (GOSE) [15], compared to those
who did not complete the QOLIBRI. Analyses of contradictory response patterns did not reveal any
peculiarities. No exclusion based on QOLIBRI response patterns was necessary for the TBI sample.
A total of 660 individuals (UK: 228, NL: 432) were, therefore, included in the further analyses. For more
details on TBI sample attrition, see Figure 2.
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2.3.1. General Population Sa ple
The study on the general population sa ple as part of the CE TER-TBI study and ethical
approval was obtained fro the Leids Universitair Centru Co issie edische Ethiek (approval
P14.222/NV/nv).
2.3.2. TBI Sample
The CENTER-TBI study (EC grant 602150) was conducted in accordance with all relevant laws of
the European Union, which were directly applicable or had a direct effect, and all relevant laws of the
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countries in which the recruiting sites were located, including but not limited to, the relevant privacy
and data protection laws and regulations (the “Privacy Law”), the relevant laws and regulations on
the use of human materials, and all relevant guidance relating to clinical studies including, but not
limited to, the ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95,
“ICH GCP”) and the World Medical Association Declaration of Helsinki entitled “Ethical Principles
for Medical Research Involving Human Subjects”. Ethical approval was obtained for each recruiting
site. The list of sites, ethical committees, approval numbers, and approval dates can be found on the
project’s website https://www.center-tbi.eu/project/ethical-approval.
2.4. Sociodemographic and Health Status Data of the All Samples
All study participants provided information regarding their age, sex, and level of education.
Individuals from the general population samples were asked if they had one or more chronic health
conditions (asthma, heart disease, stroke, diabetes, back complaints, arthrosis, rheumatism, cancer,
memory problems due to a neurological condition like dementia, memory problems due to aging,
depression, or other problems). Multiple answers were allowed.
The severity of TBI was rated by attending clinical personnel using the Glasgow Coma Scale
(GCS), with values of 3–8 indicating severe, 9–12 moderate, and 13–15 mild TBI [16]. Recovery after
TBI was rated using the Glasgow Outcome Scale Extended (GOSE) with scores of 3–4 indicating severe,
5–6 moderate disability, and 7–8 good recovery. Scores of 2 indicate a vegetative state and a score of 1
death [15].
Disease-Specific Health-Related Quality of Life after Brain Injury (QOLIBRI)
HRQoL was assessed administering the TBI-specific QOLIBRI questionnaire, which was developed
and validated in accordance with the World Health Organization definition of health [14,17]. It covers
six life domains (Cognition, Self, Autonomy and Daily life, Social Relationships, Emotions and Physical
Problems). Items contributing to the domains Emotions and Physical problems are negatively worded
(“How bothered are you by . . . ?”), the remaining items positively (“How satisfied are you with . . . ?”).
Thirty-seven items are rated on a 5-point Likert scale (“Not at all” = 1, “Slightly” = 2, “Moderately” = 3,
“Quite” = 4, “Very” = 5) and reverse coding was performed for negatively worded items. The QOLIBRI
total score is scaled to vary between 0 (worst possible HRQoL) and 100 (best possible HRQoL) [14].
As not all items were directly applicable to the general population, three items were reworded to
remove any reference to a TBI: “How satisfied are you with what you have achieved recently (instead
of “since your brain injury”)?”, “How bothered are you by the effects of any injuries you sustained?
(instead of “any other injuries you sustained at the same time as your brain injury”)”, and “Overall,
how bothered are you by the effects of any health problems? (instead of “brain injury”)”.
2.5. Statistical Analyses
The statistical analyses comprised the following steps: (1) examination of the psychometric
properties of the QOLIBRI on the item and scale level in the general population; (2) MI analyses
between groups of individuals from the TBI and general population samples and between the countries,
to ensure that the same concept of HRQoL was being measured; (3) multivariate linear regression
analyses, which examined whether country of residence, age, sex, level of education, and the presence
of chronic health conditions affected the HRQoL/QOLIBRI total score; (4) based on the regression
results, computation of reference values for individuals with and without chronic health conditions for
the QOLIBRI total score and subscales with respect to age, sex, and level of education.
Descriptive statistics (mean, standard deviation, response frequencies) were used to describe
participants’ sociodemographic and health-related data.
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2.5.1. Item Characteristics of the QOLIBRI in the General Populations
As the main focus of this study was to provide reference values for the QOLIBRI from general
population samples, item properties such as mean, standard deviation, skewness, and ceiling effects
are only reported for the general population samples. Items with absolute skewness values between
1.0 and 1.3 were interpreted as moderately skewed and not affecting further analysis [10,18]. Due to
the high variation in cut-off values for ceiling effects (15–60%) in the current literature [10,19], we set
the cut-off value at 40% (twice as high as by chance, 1/5 = 20%) for the maximum response category
“very”. Additionally, we checked if there were items with less than 10% of responses in the two lower
response categories “not at all” and “slightly”.
2.5.2. Scale Characteristics of the QOLIBRI in the General Populations
The scales’ internal consistency was determined using Cronbach’s alpha, with values between 0.7
and 0.95 indicating good to excellent internal consistency [19]. An item was defined as inconsistent
when the corrected item-total correlation coefficient (CITC) exceeded 0.4 [20]. Correlations between
the QOLIBRI domains were investigated using Pearson correlation coefficients, with values ranging
from 0.36 to 0.67, indicating a moderate linear association [21].
2.5.3. Construct Validity of the QOLIBRI in the General Populations
As a prerequisite for MI testing, construct validity was investigated in the general population
samples to ensure the comparability of the reworded and the original QOLIBRI using confirmatory
factor analysis (CFA) with the robust weighted least squares estimator (WLSMV, calculated with
the lavaan-package in R [22]). Model fit was assessed by means of the scaled chi-square statistics,
Comparative Fit Index (CFI), and root mean square error of approximation (RMSEA) with a 90-percent
confidence interval. As the standard cut-offs for CFI (>0.95) and RMSEA (<0.06) [23,24], indicating
good model fit, have not been validated for the WLSMV estimator, and they should be interpreted
with caution [25]. To address this issue, we compared fit indices across models with different
factorial structures (one common factor, two correlated factors—one containing all positively worded
“satisfaction” items, and the other one all negatively worded “bothered” items, and six correlated
factors) with higher CFI values and lower RMSEA values indicating a better model.
2.5.4. Measurement Invariance in All Samples
By using modern statistical techniques, such as MI testing, it is possible to verify whether the
questionnaire score differences between individuals, e.g., with and without TBI experience, can be
attributed to true differences in HRQoL or rather to differences in interpretation of the items and
response categories, as well as differences in items difficulty and their importance [26].
Therefore, MI testing in the framework of CFA was applied to examine whether TBI experience and
cultural/language differences influenced the comprehension of the QOLIBRI items. First, we examined
the influence of the TBI experience on the invariance of model parameters by comparing groups of
individuals from the TBI and general population samples separately for each country. To overcome
estimation problems due to the large number of estimated parameters and relatively small sizes of
the two TBI samples, the QOLIBRI items were dichotomized. The response categories “not at all”,
“slightly” and “moderately” were coded as 0, and “quite” and “very” as 1. We then investigated the
effect of the country by comparing UK and NL general population samples.
The strategy for analyzing ordinary scaled response categories suggested by Wu and Estabrook
(2016) was applied, resulting in three steps: testing of the (1) configural, (2) partial, and (3) full
invariance model. For more details, see Wu and Easterbrook [27].
For MI analyses, at least N = 200 observations per group are necessary to obtain reliable results [28].
All estimations for invariance testing (WLSMV-estimator, theta-parameterization) were performed
within the lavaan-package (version 0.6-3) [22]. For model comparisons, we applied a scaled chi-square
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difference test with the significance level set to α = 0.05. As this test has been criticized for being very
powerful in detecting small, possibly irrelevant effects in large samples [29], in case of invariance
violation, we estimated whether the effect had a practical significance for estimating the probability
of choosing a particular response category. For example, if the full invariance model (invariant
thresholds) had a significantly worse fit than the partial invariance model (noninvariant thresholds),
the probabilities of individuals from general population samples choosing a particular response
category were estimated in both models, and then compared. If the differences did not exceed 5%,
we considered the thresholds to be invariant [30].
2.5.5. Reference Values from General Population-Based Samples
As clinicians may be interested in the subjective health status and HRQoL of a single patient
after TBI, population-based reference values were calculated as percentiles. Percentiles indicate the
value below which a given percentage of observations falls. Based on this information, one can
determine whether the QOLIBRI score of an individual after TBI is below, equal to, or above the value
of the reference population. The following percentiles are provided for a patient-level interpretation:
2.5%, 5%, 16%, 30%, 40%, 50%, 60%, 70%, 85%, 95%, and 97.25%. HRQoL is considered to be impaired
when scores are one standard deviation below the average of the general population sample [31],
which corresponds to the 16%-quantile when the data are assumed to be normally distributed. Examples
are given in the results section.
Previous research has shown that 50 to 75 cases for each subgroup can already be sufficient
to provide norm values [32]. However, as several factors can influence the required sample size
(e.g., which type of norms are provided [33]), we have decided to report reference values when the
number of cases was at least N = 100. All analyses were performed in R 3.6.0 [34].
3. Results
3.1. Sociodemographic and Health-Related Data
3.1.1. General Population Sample
Study participants (N = 4403 from the UK and N = 3399 from the NL) from the general population
samples were analyzed. Individuals without a chronic health condition (UK: 2016; NL: 1572) were
differentiated from individuals with chronic health conditions (UK: 2387; NL: 1827; for details,
see Table 1). In both countries, up to 55% of individuals from the general population samples
indicated that they had at least one chronic health condition, and, in comparison with the TBI samples,
significantly more individuals described themselves as being unable to work (UK: 10%, NL: 12.8%).
3.1.2. TBI Sample
The TBI sample contained 660 individuals (N = 228 from the UK and N = 432 from the NL),
who had filled in the QOLIBRI at three months post-TBI. The majority of individuals from both TBI
samples had experienced a mild TBI (71.9% and 84.1 % in the UK and NL, respectively). In the UK,
almost half of all individuals after TBI made a good recovery 48.7% (NL: 66.2%) and 20% were still
severely disabled (NL: 8.8%) at three months post-TBI. Sociodemographic and health-related data for
all samples are presented in Table 1.
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Table 1. Sociodemographic and health-related data.
UK NL
Gen. Pop. Sample TBI Sample Gen. Pop. Sample TBI Sample
N = 4403 N = 228 p N = 3399 N = 432 p
Age in years
mean ± SD 44.52 ± 15.66 49.73 ± 17.79 <0.001 45.2 ± 15.3 55.4 ± 18.8 <0.001
Age category
18–40 1885 (42.8%) 67 (29.4%) <0.001 1338 (39.4%) 98 (22.7%) <0.001
41–64 1954 (44.4%) 113 (49.6%) 1651 (49.6%) 175 (40.5%)
65+ 564 (12.8%) 48 (21.1%) 410 (11.0%) 159 (36.8%)
Gender
Male 2134 (48.5%) 152 (66.7%) <0.001 1665 (49.0%) 253 (58.6%) <0.001
Female 2269 (51.5%) 76 (33.6%) 1734 (51.0%) 179 (41.4%)
Educational level
Low 1002 (22.8%) 7 (3.1%) <0.001 1024 (30.1%) 14 (3.3%) <0.001
Middle 1884 (42.8%) 99 (43.4%) 1526 (44.9%) 239 (55.3%)
High 1517 (34.5%) 98 (43%) 849 (25.0%) 137 (31.7%)
NA 24 (10.5%) 42 (9.7%)
Work status (before TBI)
In work 2267 (51.5%) 145 (63.6%) <0.001 1776 (52.3%) 202 (46.8%) <0.001
Out of work 399 (9.0%) 7 (3.1%) 374 (11.0%) 12 (2.8%)
Looking after others 305 (6.9%) 1 (0.4%) 145 (4.3%) 7 (1.6%)
Student 265 (6.0%) 10 (4.4%) 223 (6.6%) 34 (7.9%)
Retired 725 (16.5%) 50 (21.9%) 446 (13.1%) 143 (33.1%)
Unable to work 442 (10.0%) 3 (1.3%) 435 (12.8%) 7 (1.6%)
NA 12 (5.3%) 27 (6.2%)
Type of chronic health condition *
Asthma 602 (13.0%) - - 336 (9.4%) - -
Heart disease 109 (2.3%) - 102 (2.9%) -
Stroke 74 (1.6%) - 81 (2.3%) -
Diabetes 390 (8.4%) - 274 (7.7%) -
Back conditions 567 (12.2%) - 355 (10.0%) -
Arthrosis 141 (3.0%) - 346 (9.7%) -
Rheumatisms 192 (4.1%) - 218 (6.1%) -
Cancer 128 (2.8%) - 140 (3.9%) -
Memory problems (dementia) 82 (1.8%) - 94 (2.6%) -
Memory problems (aging) 205 (4.4%) - 82 (2.3%) -
Depression 1254 (27%) - 423 (11.9%) -
Other 493 (10.6%) - 628 (19.3%) -
Number of chronic health conditions
None 2016 (45.8%) - - 1572 (46.2%) - -
One 1379 (31.3%) - 1088 (32.0%) -
Two and more 1008 (22.9%) - 739 (21.8%) -
TBI-severity (GCS)
Mild - 164 (71.9%) - - 366 (84.7%) -
Moderate - 7 (3.1%) - 27 (6.3%)
Severe - 51 (22.4%) - 29 (6.7%)
NA - 6 (2.6%) - 10 (2.3%)
Recovery status (GOSE) at 3 months postinjury
Good recovery - 111 (48.7%) - - 286 (66.2%) -
Moderate disability - 68 (29.8%) - 107 (24.8%)
Severe disability - 47 (20.6%) - 38 (8.8%)
NA - 2 (0.9%) - 1 (0.2%)
* Type of chronic health condition: multiple answers were allowed, therefore percentages were calculated separately
for each complaint based on the total sample size; Note: UK: the United Kingdom; NL: the Netherlands; Gen. pop.:
general population sample; TBI: TBI sample; p: p-value obtained with independent samples t-test for age or with
chi-square test with Yates correction for gender, educational level, and work status; 65+: general population sample:
65–75, TBI-sample: 65–95; -: when data was not assessed; GCS: Glasgow Coma Scale; GOSE: Glasgow Outcome
Scale Extended; In work: general population sample: employee and self-employed, TBI-sample: 35+ h/week and
20–34 h/week and <20 h/week and currently on sick leave and special employment; Out of work: general population
sample: for more than 1 year and less than 1 year, TBI-Sample: unemployed; Housekeeper: general population
sample: looking after others, e.g., kids or parents; Education level: TBI-sample: “low”: currently in school and
primary school, “middle”: currently in diploma and secondary school/high school and post-high school, “high”:
college/university.
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3.1.3. Comparison of the General Population Samples with TBI Samples
In both countries, significant differences were identified between the general population samples
and the TBI samples concerning age, sex, educational level, and work status. In both general population
samples, individuals were younger than in the TBI samples (with an average age difference of five
years in the UK and of 10 years in the NL) and had a lower male incidence (UK: 48.5% vs. 66.7%,
NL: 49.0% vs. 58.6%). The rate of individuals with a high level of education (diploma, secondary/high
school, or post-high school) was lower in the general population samples compared with the TBI
samples (UK: 34.5% vs. 43%; NL: 25% vs. 31.7). In the UK, the number of working individuals was
lower in the general population sample compared with the TBI sample (51.5% vs. 63.6%, respectively),
whereas in the NL the general population sample contained more employed individuals compared
with the TBI sample (52.3% vs. 46.8%, respectively).
3.2. Item Characteristics of the QOLIBRI in the General Population Samples
On a descriptive level, there were some differences between countries concerning the item
characteristics: individuals from the UK general population sample scored lower on average but with
higher dispersion and mean values varying from 3.0 (satisfaction with sex life) to 4.1 (satisfaction
with the ability to find a way around; NL: from 3.5 to 4.2); items were less skewed ((−1; −0.2),
NL: (−1.3; −0.3)), and a ceiling effect was observed for only six items, compared with 10 in the NL
sample. All items in the UK sample and 22 items in the NL sample had over 10% responses in two
adjusted response categories “not at all” and “slightly”. For more detailed information, see Appendix A
Table A1.
3.3. Scale Characteristics of the General Population Samples
The total scale Cronbach’s alpha was high in both general population samples (UK: 0.94, NL: 0.96),
and per-scale alpha coefficients ranged between 0.86 (Emotions) and 0.95 (Cognition) in the UK general
population sample, and between 0.86 and 0.92 in the NL, indicating a very good internal consistency
of the scales. Also based on CITC, all items were found to be consistent in both samples. QOLIBRI
domains were moderately to highly correlated (UK: 0.39–0.77, NL: 0.46–0.76). For more detailed
information, see Appendix A Table A2.
3.4. Construct Validity of the General Population QOLIBRI
Based on CFA results, a six-factorial structure was most appropriate for the QOLIBRI in the UK
(χ2(614) = 15,441, p < 0.001, CFI = 0.957, RMSEA = 0.074, 90%CI (0.073; 0.075)) and also in the NL
(χ2(614) = 10,276, p < 0.001, CFI = 0.952, RMSEA = 0.068, 90%CI (0.067; 0.069)) general population
samples. For more detailed information, see Appendix A Table A3.
3.5. Measurement Invariance
When the general population and TBI samples were compared for each country, the fit of the
model with six correlated factors was not negatively affected by constraining equal intercepts, loadings,
and residuals across all groups (UK: ∆χ2(∆df) = 23.00 (25), p = 0.577, NL: ∆χ2(∆df) = 8.27 (25), p = 0.999).
However, assuming equality of thresholds resulted in significantly higher chi-square values, indicating
that some thresholds may not be invariant across groups. When UK and NL general population
samples were compared, significant, yet very small, and thus, negligible chi-square differences
(∆χ2(∆df) = 87.27 (25), p < 0.001) were observed [32]. The model fit deteriorated meaningfully when
the thresholds were restricted to be equivalent across groups (∆χ2(∆df) = 2395.26 (148), p < 0.001).
For details, see Appendix A Table A4.
More detailed analyses on the estimated thresholds using the partial invariance model showed
that the thresholds obtained in the general population sample were significantly higher than those in
the TBI sample. Comparing the UK and NL general population samples, the thresholds obtained from
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the UK sample were lower in all cases (see Appendix A, Figure A1). However, for individuals from the
general population samples, differences in the probabilities of choosing a particular response category
did not exceed 5% (Appendix A, Table A5). Therefore, the violation of the threshold invariance may be
interpreted as not significant. This implies that the QOLBRI scores can be compared between countries,
and between the general population and TBI samples. More important, differences in the QOLIBRI
scores should be attributed to “real” differences in HRQoL.
3.6. Reference Values for the General Population Samples
A significant difference in HRQoL as indicated by the QOLIBRI total score, was found between the
countries. The NL sample experienced a significantly higher HRQoL compared with the UK general
population sample (β = 8.76, p < 0.001). Regression analyses identified a significant effect of age,
level of education, presence of at least one chronic health condition, and interactions between age and
sex and health status in both general population samples. No significant effects for sex were found in
both general population samples (Table 2).
Table 2. Results of the multiple regression analyses (total sample, UK, and the NL).
Total Sample UK NL
Predictors and Interactions Reference Group B p β p β p
NL UK 8.76 <0.001 - - - -
Age (41–64) Age (18–40) 7.57 <0.001 9.36 <0.001 5.41 <0.001
Age (65–75) 13.11 <0.001 15.26 <0.001 9.91 <0.001
Sex (female) Sex (male) 0.63 0.257 0.67 0.393 0.13 0.863
Education (middle) Education (low) 3.07 <0.001 2.55 <0.001 3.57 <0.001
Education (high) 5.30 <0.001 5.35 <0.001 5.35 <0.001
Chronic health conditions (yes) Chronic health conditions (no) −16.38 <0.001 −16.70 <0.001 −15.88 <0.001
Age (41–64) × Chronic health
conditions (yes) Age (18–40) × Chronic health
conditions (no)
−0.43 0.598 −2.80 0.015 2.02 0.066
Age (65–75) × Chronic health
conditions (yes) 4.89 <0.001 4.91 0.004 4.98 0.004
Sex (female) × Chronic health
conditions (yes)
Sex (male) × Chronic health
conditions (no) −0.19 0.805 −2.05 0.057 2.58 0.012
Note: β: regression coefficient; p: p-value; bold: p-values are significant on α = 0.05.
Reference values of the general population-based samples for the QOLIBRI total score are presented
in Table 3 for the UK and Table 4 for the NL. The tables with the reference values for the QOLIBRI
subscales can be found in the Online Supplementary Materials (Table S1: UK; Table S2: NL).
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Table 3. Reference values for the Quality of Life after Traumatic Brain Injury (QOLIBRI) total score obtained from the general population UK sample stratified by sex,
health status, age, and education.
Sex × Health status × Age Low HRQoL −1 SD Md +1 SD High HRQoL
Sex Health Status Age N 2.5% 5% 16% 30% 40% 50% 60% 70% 85% 95% 97.25%
Female
Healthy
Age: 18–40 434 40 43 51 61 65 71 75 80 88 96 99
Age: 41–64 408 49 50 60 71 76 80 84 88 94 100 100
Age: 65–75 119 51 55 69 79 83 86 90 92 96 99 100
At least one chronic condition
Age: 18–40 547 16 20 33 42 46 50 56 61 71 81 87
Age: 41–64 587 12 19 36 46 50 55 61 68 79 90 94
Age: 65–75 174 31 38 50 63 66 71 76 81 88 96 99
Male
Healthy
Age: 18–40 497 40 46 51 57 63 67 73 78 86 95 99
Age: 41–64 442 49 50 59 70 75 80 83 87 95 100 100
Age: 65–75 116 54 61 72 79 83 85 88 91 96 100 100
At least one chronic condition
Age: 18–40 407 18 23 36 44 48 50 54 58 70 83 89
Age: 41–64 517 14 19 36 46 52 57 64 71 83 93 98
Age: 65–75 155 29 39 52 62 68 72 76 82 90 97 98
Sex × Health status × Education Low HRQoL −1 SD Md +1 SD High HRQoL
Sex Health Status Education N 2.5% 5% 16% 30% 40% 50% 60% 70% 85% 95% 97.25%
Female
Healthy
education: low 193 44 49 54 65 71 77 81 85 93 97 100
education: middle 383 46 49 57 67 73 79 82 87 94 100 100
education: high 385 43 48 57 66 72 76 80 86 92 98 100
At least one chronic condition
education: low 332 17 23 36 45 50 55 61 67 79 91 96
education: middle 526 11 19 34 45 49 54 60 66 76 89 92
education: high 450 16 21 38 45 50 56 62 69 78 87 93
Male
Healthy
education: low 197 41 46 54 61 71 78 81 85 95 100 100
education: middle 493 45 49 54 63 69 74 79 83 91 99 100
education: high 365 47 50 57 66 72 78 81 84 92 98 100
At least one chronic condition
education: low 280 17 21 33 46 50 53 59 66 78 93 97
education: middle 482 15 20 36 45 50 54 61 69 82 92 96
education: high 317 25 28 44 50 54 58 63 71 83 92 97
Total 4403 20 28 44 52 58 65 71 78 88 96 99
Note: HRQoL: health-related quality of life; 50% percentiles represent 50% of the distribution corresponding to the median (Md); SD: standard deviation; values from −1 standard deviation
(16%) to +1 standard deviation (85%) are within the permissible range (i.e., not impaired HRQoL). Values below 16% (no symbols) indicate impaired HRQoL and values above 85% indicate
outstanding HRQoL.
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Table 4. Reference values for the QOLIBRI total score obtained from the general population NL sample stratified by sex, health status, age, and education.
Sex × Health Status × Age Low HRQoL −1 SD Md +1 SD High HRQoL
Sex Health status Age N 2.5% 5% 16% 30% 40% 50% 60% 70% 85% 95% 97.25%
Female
Healthy
Age: 18–40 338 50 52 63 71 75 79 83 86 92 98 100
Age: 41–64 292 50 58 69 75 79 83 86 90 96 100 100
Age: 65–75 66 61 61 75 79 81 84 88 90 96 98 99
At least one chronic condition
Age: 18–40 364 32 37 49 55 60 63 68 73 81 87 92
Age: 41–64 527 38 44 54 62 66 71 75 79 87 94 96
Age: 65–75 147 47 52 63 69 73 75 80 83 88 93 94
Male
Healthy
Age: 18–40 388 49 50 57 69 74 77 81 86 94 100 100
Age: 41–64 396 53 56 68 75 79 83 89 92 96 100 100
Age: 65–75 92 65 73 77 81 84 88 91 93 96 99 100
At least one chronic condition
Age: 18–40 248 30 38 48 52 54 57 60 67 77 88 91
Age: 41–64 436 31 37 50 58 63 69 73 77 86 95 98
Age: 65–75 105 47 51 61 69 75 80 83 86 92 96 97
Sex × Health Status × Education Low HRQoL −1 SD Md +1 SD High HRQoL
Sex Health status Education N 2.5% 5% 16% 30% 40% 50% 60% 70% 85% 95% 97.25%
Female
Healthy
education: low 171 49 50 61 70 75 79 82 86 94 99 100
education: middle 341 50 56 68 75 78 81 84 88 95 100 100
education: high 184 51 59 69 75 79 84 86 88 93 98 99
At least one chronic condition
education: low 374 34 41 52 59 65 68 73 78 84 91 96
education: middle 477 34 42 52 60 64 69 73 78 85 92 96
education: high 187 43 48 54 63 67 71 76 80 86 92 95
Male
Healthy
education: low 202 50 50 60 71 76 79 82 88 95 99 100
education: middle 394 50 54 65 74 77 81 85 92 96 100 100
education: high 280 50 52 66 75 79 83 88 91 96 100 100
At least one chronic condition
education: low 277 30 35 50 57 61 66 70 75 83 93 96
education: middle 314 32 41 49 56 59 66 72 77 86 96 98
education: high 198 36 42 50 57 62 68 72 79 87 92 95
Total 3399 39 46 55 65 71 75 79 83 92 98 100
Note: HRQoL: health-related quality of life; 50% percentiles represent 50% of the distribution corresponding to the median (Md); SD: standard deviation; values from −1 standard
deviation (16%) to +1 standard deviation (85%) are within the normal range (i.e., not impaired HRQoL); Values below 16% indicate impaired HRQoL and values above 85% indicate
outstanding HRQoL.
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The following example illustrates how to apply these norms. After a TBI, a 70-year-old woman
from the UK without any chronic health condition reports a QOLIBRI total score of 75. The table
depicts that around 20% of healthy individuals in her age group reported the same level of HRQoL or
a lower HRQoL. In other words, 80% of the reference population experience better HRQoL. Should
a chronic health condition be known, 60% of the reference population from her age and health status
group report better HRQoL and 40% of the general population with similar conditions experience
a better HRQoL than she does.
Based on the 16%-percentile cut-off value, HRQoL is interpreted as impaired for female healthy
individuals in the age range of 64–75 years when the QOLIBRI total score is under 69, or under 50 if
any chronic health condition is reported. The score of 75 exceeds both cut-off values and can, therefore,
be interpreted as indicating that she is not impaired (compared with individuals from the UK general
population aged between 65–75 years with and without any chronic health condition).
4. Discussion
The aim of our study was to enhance the interpretability of disease-specific HRQoL after
TBI using the QOLIBRI by establishing reference values from general population samples in the
UK and the NL, based on representative quotas with regard to sex, age, and educational level.
The representation of these characteristics corresponds to their distribution in the UK and the
NL general populations (e.g., see the Organisation for Economic Co-operation and Development
(OECD) [35] for sociodemographic characteristics in European countries). In this respect, the data from
our general population samples are comparable to the general population of each country. This study is
unique, as such general population-based reference values are currently not available for the QOLIBRI.
The results indicated that the reworded QOLIBRI is applicable to general population samples and
displays good psychometric properties. Measurement invariance testing demonstrated that for the six
HRQoL subdomains, all QOLIBRI items have the same meaning for individuals with and without
a TBI experience and in the different countries. Therefore, we conclude that the QOLIBRI scores can be
compared across general population samples and TBI samples in the UK and the NL. The differences
in the scores have to be explained by “real” differences in HRQoL and not by other factors, such as
differences in the understanding of items or response categories. Thus, we were able to establish
population-based reference values.
In previous research, individuals from the NL general population reported higher mental summary
component scores in the SF-36 in comparison to seven other countries, including five European
countries [36]. Lower HRQoL was associated with the presence of chronic health conditions [37].
Our results replicate these findings, with individuals from the NL general population sample reporting
significantly higher HRQoL compared to those from the UK. Previous findings concerning the
association of HRQoL with age are ambiguous: in the general populations of Norway and Canada,
higher age was positively associated with the mental summary component score of the SF-36 and
negatively with the physical summary component [38,39]. Our data showed that older individuals
from the general population samples from both countries and subsamples with and without chronic
health conditions report better HRQoL. Our study did not identify any sex differences in the two
countries, with the exception of the subgroups with and without any chronic health conditions in
the NL sample. This finding is also comparable to a study assessing the generic HRQoL by means of
the SF-36: here only the general health perception scale was sensitive to sex differences, with females
reporting lower generic HRQoL [8,40].
Previously, the interpretation of the QOLIBRI total score was facilitated through a cross-walk
analysis with the mental component summary score of the SF-36, for which US population-based norms
were used [41]. HRQoL was considered to be impaired when scores were one standard deviation below
the average of the general population sample [35]. Therefore, QOLIBRI values under 60 indicated
impaired disease-specific HRQoL [41]. Our reference values provide a country-adapted basis because
they were obtained from general population samples. Here, cut-off values of 56 for the UK and 65 for
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the NL should be taken to identify impaired TBI-specific HRQoL when comparing individuals after
TBI with healthy individuals. As we found significant differences between the countries, we strongly
recommend using the respective population-based reference values presented in the current study
when the QOLIBRI is applied.
Strengths and Limitations
A strength of the present study is the large size of the general population samples, which allowed
for high-powered statistical analyses. The stratification into healthy individuals and those having
reported at least one chronic health complaint offers an additional possibility for the interpretation of
HRQoL of individuals after TBI.
The representativity of the recruited samples may be questioned. First, the selection of participants
was based on different web-based panels. This might have led to different selection biases, even when
several platforms were used for recruiting in order to increase the representativity of different groups.
Second, no information was available from the survey agency concerning participants who were
contacted but did not take part in the survey. In other words, it was not possible to determine how many
and which individuals could have potentially participated in the study, as a means of demonstrating
a selection bias. Third, answers given in the online survey could be associated with (self-)selection and
nonresponse bias [42,43], as some individuals may systematically participate in online surveys.
Yet, the sampling procedure was strictly based on demographic characteristics such as age, sex,
and education, and on a very large panel involving individuals from different sources. The quota
sampling with respect to age, sex, and level of education corresponded to the distribution in the general
populations of the two countries (see OECD statistics [35]). Therefore, the samples seem valid for
providing reference values to evaluate the degree of impairment of HRQoL in individuals after TBI.
Another limitation was the lack of precise information concerning previously experienced TBIs in
the general population samples. However, the estimated TBI prevalence based on reported age-adjusted
hospital discharge rates due to TBI is quite low and reaches 312.7 per 100,000 in the UK and 173.7
per 100,000 in the NL [44]. Thus, the presence of individuals, who experienced TBI in the general
population samples, was very unlikely to cause a bias concerning the reference values and evaluation
of HRQoL.
The baseline characteristics of the general and the TBI sample displayed differences with regard
to sex, age, and education status. However, such differences are unavoidable bearing in mind the two
times higher prevalence of TBI among males [45] and increasing TBI incidence in elderly people [46],
resulting in differences in work status distribution, and in higher rates of retired individuals in the
TBI samples.
Furthermore, the relatively small sizes of the TBI samples required dichotomization of the
QOLIBRI response categories for MI testing, which is associated with a loss of information concerning
response patterns. However, the TBI sample was only used to ensure the methodological comparability
of the QOLIBRI in general population samples by MI analyses. It turned out that the factorial structure
and the understanding of the HRQoL construct measured by the QOLIBRI were comparable between
the general population samples and the TBI samples in both countries. Thus, the reference values
established here are reliable.
5. Conclusions
This paper aimed to provide a basis for a better understanding of HRQoL after TBI in research
and clinical practice. For this purpose, population-based reference values were developed to add
value to the interpretation and clinical meaningfulness of QOLIBRI scores of individuals after TBI.
Significant differences in the reported levels of HRQoL were found between the UK and the NL
general population samples as well as between the TBI and the general population samples. Therefore,
we have presented population-based reference values separately for the two countries. We recommend
establishing population-based reference values also for other countries in future research, especially
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for lower-income countries, as these are a key component for understanding therapeutic progress in
individual cases and enabling research on HRQoL.
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Appendix A
Table A1. Characteristics of the QOLIBRI items.
General Population Sample
UK NL UK NL UK NL UK NL
QOLIBRI Items Mean ± SD Skewness Ceiling (%) % “Not at All”and “Slightly”
Cognition 71.1 ± 24.4 78.4 ± 18.1 −0.8 −0.9 15.1 16.8 - -
Concentrate 3.7 ± 1.2 4.0 ± 0.9 −0.6 −1 30.4 34.5 17 7
Express yourself 3.8 ± 1.1 4.1 ± 0.9 −0.8 −1.1 35.2 38 13 6
Memory 3.7 ± 1.1 4.1 ± 0.9 −0.6 −1 26.8 33.8 15 6
Plan and problem solve 3.9 ± 1.1 4.2 ± 0.9 −0.8 −1.2 35 41 12 5
Decisions 3.9 ± 1.1 4.1 ± 0.9 −0.9 −1.1 38.6 39 11 5
Navigate 4.1 ± 1.1 4.2 ± 0.9 −1 −1.2 46.2 44.7 10 4
Speed of thinking 3.9 ± 1.1 4.2 ± 0.9 −0.8 −1.2 32.7 39.6 12 5
Self 54.8 ± 27.4 68.6 ± 20.3 −0.2 −0.7 6.2 6.4 - -
Energy 3.2 ± 1.2 3.5 ± 1.0 −0.3 −0.6 13 15.1 27 15
Motivation 3.2 ± 1.2 3.7 ± 1.0 −0.3 −0.7 15.4 21.2 26 11
Self-esteem 3.2 ± 1.3 3.8 ± 1.0 −0.2 −0.8 17.2 28.2 30 11
Appearance 3.1 ± 1.2 3.8 ± 1.0 −0.2 −0.8 13.4 20.2 31 10
Achievements 3.2 ± 1.2 3.8 ± 1.0 −0.2 −0.8 16.2 25.8 29 11
Self-perception 3.2 ± 1.2 3.8 ± 1.0 −0.3 −0.9 14.8 21.7 28 11
Future 3.2 ± 1.2 3.7 ± 1.0 −0.2 −0.8 15.4 21.5 29 12
Daily life and autonomy 66.5 ± 26.2 75.5 ± 19.4 −0.6 −0.8 11.9 13.2 - -
Independence 3.7 ± 1.2 4.1 ± 1.0 −0.7 −1 33.3 38.4 16 7
Get out and about 3.8 ± 1.2 4.2 ± 0.9 −0.8 −1.3 40.2 45.3 16 5
Domestic activities 3.9 ± 1.2 4.1 ± 1.0 −0.8 −1.1 40.7 42.5 15 7
Run personal finances 3.8 ± 1.2 4.2 ± 0.9 −0.8 −1.2 36.7 43.5 16 6
Participation work 3.5 ± 1.3 3.8 ± 1.2 −0.5 −0.9 27.4 30.6 22 15
Social and leisure activities 3.3 ± 1.3 3.8 ± 1.1 −0.3 −0.8 21.5 26.9 28 13
In charge of life 3.6 ± 1.2 4.0 ± 0.9 −0.6 −1 28.8 35 18 7
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Table A1. Cont.
General Population Sample
UK NL UK NL UK NL UK NL
QOLIBRI Items Mean ± SD Skewness Ceiling (%) % “Not at All”and “Slightly”
Social relationships 63.9 ± 26.0 74.0 ± 19.6 −0.5 −0.8 11 11.5 - -
Affection towards others 3.8 ± 1.2 4.2 ± 0.9 −0.7 −1.2 34 43.9 15 6
Family 3.8 ± 1.2 4.0 ± 1.0 −0.7 −1 33.8 35.9 15 8
Friends 3.6 ± 1.2 4.0 ± 0.9 −0.6 −1.1 28.8 34.9 18 7
Partner 3.7 ± 1.3 4.0 ± 1.1 −0.7 −1.1 37.1 43 19 10
Sex life 3.0 ± 1.4 3.5 ± 1.2 −0.1 −0.7 20.6 23.9 35 19
Attitudes of others 3.4 ± 1.1 3.9 ± 0.9 −0.4 −0.9 19.7 26.4 19 7
Emotions 59.4 ± 28.0 68.4 ± 24.4 −0.2 −0.4 11.6 15.4 - -
Feel lonely 3.5 ± 1.3 3.5 ± 1.3 −0.4 −0.3 32.1 29.2 24 25
Feel bored 3.4 ± 1.3 3.6 ± 1.2 −0.3 −0.5 26.2 28.2 26 20
Feel anxious 3.3 ± 1.4 3.7 ± 1.2 −0.2 −0.6 25.1 35.2 32 15
Feel sad 3.3 ± 1.4 3.7 ± 1.3 −0.2 −0.6 27 35.5 31 18
Feel angry 3.6 ± 1.3 3.9 ± 1.2 −0.5 −0.8 34.7 41.6 22 13
Physical problems 66.8 ± 27.0 70.0 ± 23.5 −0.5 −0.5 15.6 15.3 - -
Slow/clumsiness 3.8 ± 1.2 3.9 ± 1.1 −0.7 −0.7 40.8 38.8 17 14
Effects injuries 3.9 ± 1.2 3.9 ± 1.2 −0.8 −0.9 46.4 47.2 15 16
Pain 3.5 ± 1.3 3.6 ± 1.2 −0.4 −0.4 28.6 28.8 23 22
See/hear 4.0 ± 1.2 4.0 ± 1.1 −0.9 −0.8 46 40.1 14 11
Effects health problems 3.5 ± 1.3 3.7 ± 1.2 −0.4 −0.5 28.8 31.1 23 19
QOLIBRI total score 63.8 ± 20.6 72.8 ± 16.6 −0.3 −0.5 1.6 1.9 - -
Note: Mean: mean value; SD: standard deviation; ceiling effects are expressed as a percentage and represent the
proportion of individuals who chose the response category “very” on the QOLIBRI items or reached the maximum
of 100 on the respective QOLIBRI scales.
Table A2. Psychometric properties of the QOLIBRI scales.
Cronbach’s Alpha Item-TotalCorrelation Range Correlations between Subscales Scores
UK general population sample
QOLIBRI domain (1) (2) (3) (4) (5)
Cognition (1) 0.94 0.77–0.83 1
Self (2) 0.95 0.76–0.87 0.67 1
Daily life and autonomy (3) 0.93 0.71–0.81 0.75 0.77 1
Social relationships (4) 0.9 0.60–0.76 0.65 0.73 0.71 1
Emotions (5) 0.87 0.62–0.79 0.46 0.51 0.49 0.47 1
Physical problems (6) 0.88 0.61–0.74 0.5 0.44 0.55 0.39 0.48
NL general population sample
QOLIBRI domain (1) (2) (3) (4) (5)
Cognition (1) 0.92 0.69–0.77 1
Self (2) 0.92 0.70–0.81 0.68 1
Daily life and autonomy (3) 0.89 0.61–0.73 0.7 0.76 1
Social relationships (4) 0.86 0.60–0.72 0.58 0.66 0.66 1
Emotions (5) 0.88 0.72–0.82 0.54 0.57 0.56 0.55 1
Physical problems (6) 0.86 0.54–0.78 0.52 0.57 0.62 0.45 0.49
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Table A3. Results of confirmatory factor analyses.
UK General Population Sample
Model Comparison
Model with
Factors CFI RMSEA (90%CI) χ
2 (df) p Model withFactors ∆χ
2 (∆df) p
one 0.802 0.156 (0.155; 0.157) 68,302 (629) <0.001
two 0.889 0.117 (0.116; 0.118) 38,601 (628) <0.001 one vs. two 3111.5 (1) <0.001
six 0.957 0.074 (0.073; 0.075) 15,441 (614) <0.001 two vs. six 5696.1 (14) <0.001
NL General Population Sample
Model Comparison
Model with
Factors CFI RMSEA (90%CI) χ
2(df) p Model withFactors ∆χ
2(∆df) p
one 0.8 0.137 (0.136; 0.138) 40,659 (629) <0.001
two 0.868 0.111 (0.110; 0.113) 27,135 (628) <0.001 one vs. two 1725.3 (1) <0.001
six 0.952 0.068 (0.067; 0.069) 10,276 (614) <0.001 two vs. six 4313.8 (14) <0.001
Note: CFI: scaled Comparative Fit Index; RMSEA (90%CI): scaled root mean square error of approximation with
90% confidence interval; χ2: scaled chi-square statistics; df: scaled degrees of freedom; p: p-value of chi-square
(difference) statistics; ∆χ2: difference in chi-square statistics under Sattora.Bentler.2001 correction; ∆df: difference in
degrees of freedom.
Table A4. Results of measurement invariance testing.
UK: General Population Sample vs. TBI Sample
Model Comparison
CFI RMSEA (90%CI) χ2 (df) p Invariance Models ∆χ2 (∆df) P
0.989 0.033 (0.032; 0.034) 4264 (1228) <0.001
0.991 0.029 (0.028; 0.031) 4740 (1253) <0.001 Configural vs. partial 23.00 (25) 0.577
0.991 0.029 (0.028; 0.030) 4854 (1290) <0.001 Partial vs. full 66.95 (37) 0.002
NL: General Population Sample vs. TBI Sample
Model Comparison
CFI RMSEA (90%CI) χ2 (df) p Invariance Models ∆χ2 (∆df) P
0.983 0.032 (0.031; 0.034) 3409 (1228) <0.001
0.986 0.029 (0.027; 0.030) 3544 (1253) <0.001 Configural vs. partial 8.27 (25) 0.999
0.986 0.029 (0.028; 0.030) 3702 (1290) <0.001 Partial vs. full 108.10 (37) <0.001
UK vs. NL: General Population Samples
Model Comparison
CFI RMSEA (90%CI) χ2 (df) p Invariance Models ∆χ2 (∆df) P
0.956 0.071 (0.071; 0.072) 16696 (1228) <0.001
0.966 0.062 (0.061; 0.063) 17884 (2153) <0.001 Configural vs. partial 87.27 (25) <0.001
0.962 0.062 (0.061; 0.063) 20051 (1410) <0.001 Partial vs. full 2395.26 (148) <0.001
Note: CFI: scaled Comparative Fit Index; RMSEA (90%CI): scaled root mean square error of approximation with 90%
confidence interval; χ2: scaled chi-square statistics; df: scaled degrees of freedom; p: p-value of chi-square (difference)
statistics; ∆χ2: difference in chi-square statistics under Sattora-Bentler (2001) correction; ∆df: difference in degrees of
freedom; Identification constraints for the invariance models: Configural: item intercepts = 0, residual variances = 1,
latent factor means = 0, latent factor variances = 1 Partial: item intercepts = 0, residual variances = 1. Only in the
reference group latent factor means = 0 and variances = 1; Full: item intercepts = 0, residual variances = 1. Only in
the reference group factor means = 0, factor variances = 1.
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Table A5. Response probabilities (RP) of the UK and NL general population samples to choose a response category estimated in the partial invariance model and their
differences to the response probabilities estimated within the full invariance model.
UK Gen. Pop.
(TBI as a Ref.) a
NL Gen. Pop.
(TBI as a Ref.) b NL Gen. Pop. (UK as a Reference)
c
Cognition 1 d 1 d Not at All Slightly Moderately Quite Very
Concentrate 0.614 (0.001) 0.777 (0.001) 0.050 (−0.001) 0.124 (0.012) 0.213 (0.014) 0.309 (−0.039) 0.304 (0.013)
Express yourself 0.670 (−0.003) 0.814 (−0.004) 0.038 (−0.001) 0.097 (0.005) 0.195 (0.013) 0.318 (−0.041) 0.352 (0.023)
Memory 0.624 (0.004) 0.793 (0.004) 0.042 (−0.001) 0.109 (0.009) 0.225 (0.022) 0.355 (−0.027) 0.268 (−0.003)
Plan and problem solve 0.685 (0.001) 0.841 (−0.001) 0.033 (−0.001) 0.086 (0.005) 0.196 (0.020) 0.334 (−0.035) 0.350 (0.011)
Decisions 0.705 (0.000) 0.824 (−0.001) 0.034 (−0.004) 0.080 (0.001) 0.181 (0.008) 0.319 (−0.043) 0.386 (0.038)
Navigate 0.747 (−0.004) 0.843 (−0.005) 0.026 (−0.002) 0.071 (0.001) 0.157 (0.001) 0.285 (−0.049) 0.462 (0.049)
Speed of thinking 0.677 (0.003) 0.836 (0.006) 0.032 (−0.004) 0.086 (0.007) 0.205 (0.022) 0.350 (−0.029) 0.327 (0.005)
Self
Energy 0.431 (0.006) 0.589 (0.007) 0.116 (−0.014) 0.157 (−0.012) 0.296 (0.010) 0.300 (−0.005) 0.130 (0.020)
Motivation 0.448 (0.003) 0.667 (0.008) 0.109 (−0.003) 0.156 (−0.006) 0.288 (0.017) 0.294 (−0.021) 0.154 (0.013)
Self-esteem 0.438 (0.001) 0.696 (0.000) 0.129 (−0.003) 0.173 (0.006) 0.260 (0.020) 0.266 (−0.022) 0.172 (0.000)
Appearance 0.409 (−0.001) 0.69 (−0.008) 0.136 (0.004) 0.178 (0.018) 0.277 (0.022) 0.275 (−0.048) 0.134 (0.004)
Achievements 0.438 (−0.006) 0.69 (−0.003) 0.120 (−0.006) 0.166 (0.005) 0.275 (0.025) 0.276 (−0.025) 0.162 (0.001)
Self-perception 0.443 (−0.001) 0.701 (−0.003) 0.118 (−0.007) 0.166 (0.006) 0.273 (0.024) 0.295 (−0.031) 0.148 (0.008)
Future 0.433 (−0.002) 0.677 (−0.001) 0.123 (−0.008) 0.163 (0.005) 0.282 (0.025) 0.279 (−0.033) 0.154 (0.011)
Daily life & Autonomy
Independence 0.623 (−0.003) 0.771 (−0.003) 0.056 (−0.003) 0.105 (0.005) 0.216 (0.009) 0.290 (−0.028) 0.333 (0.017)
Get out and about 0.655 (0.003) 0.836 (−0.001) 0.060 (0.001) 0.100 (0.012) 0.185 (0.014) 0.253 (−0.052) 0.402 (0.025)
Domestic activities 0.672 (−0.001) 0.791 (−0.001) 0.052 (−0.004) 0.095 (0.002) 0.182 (−0.001) 0.265 (−0.036) 0.407 (0.039)
Run personal finances 0.650 (−0.003) 0.81 (−0.004) 0.057 (0.000) 0.099 (0.009) 0.194 (0.013) 0.283 (−0.033) 0.367 (0.011)
Participation work 0.554 (0.003) 0.677 (0.007) 0.115 (−0.012) 0.100 (−0.010) 0.231 (0.022) 0.280 (−0.018) 0.274 (0.017)
Social and leisure activities 0.472 (0.001) 0.662 (0.005) 0.129 (0.007) 0.153 (0.010) 0.246 (0.016) 0.257 (−0.034) 0.215 (0.002)
In charge of life 0.584 (0.000) 0.773 (−0.001) 0.069 (−0.003) 0.114 (0.009) 0.233 (0.018) 0.296 (−0.033) 0.288 (0.010)
Social relationships
Affection towards others 0.627 (−0.002) 0.806 (−0.001) 0.050 (−0.004) 0.105 (0.008) 0.218 (0.012) 0.287 (−0.030) 0.340 (0.014)
Family 0.633 (−0.001) 0.758 (−0.005) 0.057 (−0.007) 0.096 (−0.003) 0.213 (0.003) 0.295 (−0.035) 0.338 (0.042)
Friends 0.593 (−0.002) 0.784 (−0.002) 0.072 (0.000) 0.110 (0.007) 0.225 (0.013) 0.305 (−0.044) 0.288 (0.023)
Partner 0.615 (0.000) 0.758 (0.000) 0.102 (−0.001) 0.092 (−0.001) 0.191 (0.005) 0.244 (−0.032) 0.371 (0.028)
Sex life 0.425 (0.005) 0.591 (0.010) 0.234 (0.021) 0.120 (0.001) 0.221 (0.000) 0.218 (−0.039) 0.206 (0.017)
Attitudes of others 0.517 (0.000) 0.766 (0.000) 0.070 (0.001) 0.124 (0.010) 0.289 (0.031) 0.320 (−0.053) 0.197 (0.010)
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Table A5. Cont.
UK Gen. Pop.
(TBI as a Ref.) a
NL Gen. Pop.
(TBI as a Ref.) b NL Gen. Pop. (UK as a Reference)
c
Cognition 1 d 1 d Not at All Slightly Moderately Quite Very
Emotions
Feel lonely 0.529 (−0.004) 0.534 (−0.010) 0.079 (−0.003) 0.160 (−0.035) 0.232 (−0.002) 0.208 (−0.006) 0.321(0.046)
Feel bored 0.494 (0.000) 0.589 (−0.003) 0.089 (0.006) 0.171 (−0.010) 0.245 (0.002) 0.232 (−0.023) 0.262(0.026)
Feel anxious 0.463 (0.002) 0.633 (−0.001) 0.136 (0.022) 0.181 (0.008) 0.219 (−0.010) 0.212 (−0.021) 0.251 (0.001)
Feel sad 0.474 (0.003) 0.620 (0.010) 0.138 (0.018) 0.171 (−0.007) 0.217 (−0.005) 0.204 (−0.018) 0.270 (0.011)
Feel angry 0.567 (−0.002) 0.695 (0.002) 0.082 (0.008) 0.136 (−0.001) 0.214 (0.003) 0.22 (−0.022) 0.347 (0.012)
Physical problems
Slow/clumsiness 0.612 (0.002) 0.649 (0.002) 0.055 (0.008) 0.118 (−0.005) 0.214 (0.003) 0.204 (−0.021) 0.408 (0.015)
Effects injuries 0.658 (0.005) 0.679 (0.013) 0.048 (−0.004) 0.105 (−0.011) 0.189 (0.014) 0.194 (−0.003) 0.464 (0.004)
Pain 0.545 (−0.002) 0.542 (−0.010) 0.088 (0.006) 0.146 (−0.010) 0.221 (−0.007) 0.260 (0.009) 0.286 (0.002)
See/hear 0.674 (0.000) 0.688 (0.002) 0.041 (0.004) 0.098 (0.001) 0.187 (−0.008) 0.215 (−0.029) 0.460 (0.032)
Effects health problems 0.534 (−0.004) 0.595 (−0.006) 0.090 (0.011) 0.143 (−0.004) 0.233 (0.009) 0.245 (−0.010) 0.288 (−0.007)
Note. a Probabilities estimated for the NL general population sample from the invariance model comparing TBI and general population sample; b Probabilities estimated for the UK
general population sample from the invariance model comparing TBI and general population sample; c Probabilities estimated for the NL general population sample from the invariance
model comparing UK and NL general population samples; d For measurement invariance testing with TBI samples response categories “not at all” and “slightly” were recorded as 1.
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